Marinus Pharmaceuticals, Inc., a pharmaceutical company that specializes in therapeutic products for rare genetic epilepsies and seizure disorders, announced the launch of its newest product, ZTALMY (ganaxolone). This oral suspension is tailored to target seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for both adult and pediatric patients in self-administered or in-patient care settings. Marinus Pharmaceuticals asserts that ZTALMY's active ingredient, ganaxolone, targets synaptic and extrasynaptic GABAA receptors, leading to an anti-seizure, antidepressant, and anxiolytic effect. The company is also actively developing ganaxolone to treat a wide range of genetic epilepsy disorders, such as PCDH19-related epilepsy and tuberous sclerosis complex. Under license agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., and a collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd., Marinus Pharmaceuticals is headquartered in Radnor, Pennsylvania, and has been in operation since 2003.